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Abstract
The natural reservoirs of influenza viruses are aquatic birds. After adaptation, avian viruses can
acquire the ability to infect humans and cause severe disease. Because domestic poultry serves as a
key link between the natural reservoir of influenza viruses and epidemics and pandemics in human
populations, an effective measure to control influenza would be to eliminate or reduce influenza virus
infection in domestic poultry. The development and distribution of influenza-resistant poultry
represents a proactive strategy for controlling the origin of influenza epidemics and pandemics in
both poultry and human populations. Recent developments in RNA interference and transgenesis in
birds should facilitate the development of influenza-resistant poultry.
The influenza A virus is an enveloped, segmented RNA virus and the etiological agent of
influenza epidemics and pandemics in both poultry and human populations [1]. In a typical
year, influenza viruses infect as many as 500 million people worldwide and cause >500,000
deaths. During a pandemic, the loss of life is even more staggering: the devastating 1918–1919
pandemic killed ∼40–50 million people, causing global political, social, and economic
dislocations.
INFLUENZA PROPHYLAXIS AND THERAPEUTICS
Currently, vaccination with killed or cold-adapted viruses is the preferred method of controlling
influenza. However, the existing influenza vaccines have several drawbacks. First, the most
commonly used vaccines (inactive viruses) prevent illness from infection in only 70%–90%
of healthy adults and only 30%–40% of members of high-risk groups (infants, elderly
individuals, immunocompromised individuals, and patients with chronic underlying diseases)
[2]. Second, the influenza viruses incorporated into the vaccines are selected on the basis of
surveillance data of recent prevalent strains. This best-guess method of predicting future
circulating strains cannot account for and, thus, does not protect against unexpected strains or
unanticipated pandemics. Third, the 4–6-month period required for formulating a new virus
strain into vaccines and ramping up large-scale production of the new vaccines is too long to
meet the demand during a crisis situation created by a rapidly moving pandemic. Finally,
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adverse effects associated with current vaccines and the technical and regulatory hurdles for
producing a new vaccine should not be underestimated.
There currently are 4 antiviral drugs for the treatment and prophylaxis of influenza. These
drugs fall into 2 categories: M2 inhibitors (amantadine and rimantadine) and neuraminidase
(NA) inhibitors (zanamivir and oseltamivir). Although these compounds can be used as
chemoprophylactics, they are not substitutes for vaccination. Rather, they are used as adjuncts
in controlling outbreaks of influenza virus infection. To be effective, the antiviral drugs have
to be administered within the first 24–48 h after the development of symptoms. In addition,
adverse effects, compliance problems, limited supply, and high costs preclude the widespread
use of these antiviral drugs. Of still greater concern is the emergence of stable and transmissible
drug-resistant strains of influenza virus [3]. Because of widespread resistance to rimantadine
and amantadine, the Centers for Disease Control and Prevention advised physicians in January
2006 to stop prescribing these drugs for seasonal influenza virus infections. Similarly, influenza
viruses that are resistant to NA inhibitors have been isolated from clinical samples [4]. This
raises a serious concern about the widespread use of NA inhibitors.
DEVELOPMENT OF INFLUENZA-RESISTANT POULTRY AS A
FUNDAMENTALLY NEW STRATEGY FOR INFLUENZA CONTROL
The imminent threat of a global influenza pandemic caused by the avian influenza A(H5N1)
virus demands the rapid development of new vaccines and the stockpiling of existing antiviral
drugs. However, the limited efficacy and scope of current vaccines and antiviral drugs also
demands the development of fundamentally new strategies to control influenza epidemics and
pandemics. The natural reservoirs of influenza virus are aquatic birds and wild fowl, in which
many different virus strains are circulating at any one time [5]. Viruses frequently are
transmitted from wild species to domestic birds, causing devastating epidemics and pandemics
in poultry populations. Avian viruses usually require adaptation before they can infect humans,
although the current avian influenza A(H5N1) virus has been documented to infect humans
directly and to cause severe disease. Annual influenza epidemics in human populations,
including the documented outbreaks of 1997, 2003, and 2005, as well as the worldwide
pandemics of 1918, 1958, and 1968, have been traced to avian sources [5,6]. Influenza
epidemics and pandemics are likely to intermittently cause havoc in poultry and human
populations for the foreseeable future, unless effective long-term control can be achieved.
Since domestic poultry serves as a key link between the natural reservoir of influenza viruses
and epidemics and pandemics in human populations, an effective measure to control influenza
would be to eliminate or reduce influenza virus infection in domestic poultry, to reduce the
probability that avian influenza virus variants with pandemic-causing potential will arise. One
approach to developing transgenic poultry that are resistant to influenza viruses is to use RNA-
interference (RNAi) technology. The development and distribution of influenza-resistant
poultry represents a fundamentally new strategy for controlling influenza epidemics and
pandemics at their origins, in both poultry and human populations. The strategy should
complement current approaches of influenza control through the use of vaccines and antiviral
drugs.
TECHNOLOGIES FOR DEVELOPING INFLUENZA-RESISTANT POULTRY
RNAi is an evolutionarily conserved process in metazoans by which double-stranded RNA
directs sequence-specific degradation of mRNA. Studies have shown that RNAi can be
triggered by the introduction of synthetic 21-nt RNA duplexes [7], often referred to as “short
interfering RNA” (siRNA), or by the expression of RNA duplexes in a hairpin structure [8],
referred to as “short hairpin RNA” (shRNA), which can be processed into siRNA by cellular
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RNA endonucleases. RNAi has been shown to be effective in interfering with viruses such as
HIV, hepatitis B virus, respiratory syncytial virus, poliovirus, rhinovirus, severe acute
respiratory syndrome—associated coronavirus, and dengue virus in cell culture and, in a few
cases, in animals.
Directly relevant to influenza control, studies have shown that siRNA that is specific for
conserved regions of influenza virus genes potently inhibit replication of a broad spectrum of
influenza viruses in cell lines, chicken embryos, and mice [9,10]. Stable expression of
influenza-specific shRNA via a lentiviral vector in a cell line renders the cells refractory to
influenza virus infection [10]. Similarly, introduction of the same lentiviral vector into the
mouse lung results in significant inhibition of virus production in vivo. Together, these findings
suggest the possibility of developing influenza-resistant poultry by transgenic expression of
influenza-specific shRNA.
Lentivirus has been the vector of choice for stable expression of shRNA in cells and animals
[11]. Recently, lentivirus-mediated transgenesis has been shown to be very efficient in birds.
More than 70% of founder birds contain the vector sequences, and 4%–45% of founder birds
give rise to germline transmission [12,13]. In contrast, transgenesis in chickens by direct DNA
injection or infection with oncoretroviral vectors is much less efficient, often requiring the
screening of thousands of birds to obtain a single germline transmission [14]. Furthermore,
unlike transgene expression from oncoretroviral vectors, which is often silenced by epigenetic
modifications during early ontogeny, transgene expression from integrated lentiviral vectors
has been found to be stable for 4 generations (B.B.S. and C.L., unpublished data).
A critical consideration in developing influenza-resistant poultry is the prevention of the
emergence of resistant viruses. One approach is to use siRNA targeting the conserved regions
of influenza virus genes, because these regions either do not change or change much less
frequently than do other regions, probably owing to structural and/or functional constraints.
Targeting the highly conserved region potentially allows the siRNA to remain effective despite
antigenic drift and shift. It also has the potential to reduce the emergence of viable resistant
variants. Another approach is to simultaneously express multiple shRNAs. The mutation rate
of influenza virus is estimated to be 1.5 × 10-5 mutations/nucleotide/infection cycle [15]. If 4
shRNAs are expressed simultaneously, the probability of the emergence of a resistant virus
can be reduced to 1 resistant virus/3 × 1021 virions. This probability can be assessed by use of
the following example. The United States produced ∼9 billion broiler chickens in 2006. For a
resistant virus to arise, each chicken would have to produce 3 × 1011 infectious virions. Under
the assumption that 1 infected cell produces 3 × 103 new infectious virions, 108 cells/chicken
would have to be infected. Thus, lentiviral vectors expressing ≥4 shRNAs specific for the
conserved regions of the influenza virus genome should be used for transgenic poultry
production.
TECHNICAL, LOGISTICAL, AND SOCIAL CONSIDERATIONS
The development and distribution of influenza-resistant poultry for the control of influenza in
both poultry and human populations will be likely to face significant technical, logistical, and
social challenges. First, technologies for producing influenza-resistant poultry have not been
demonstrated experimentally. Although cells can be rendered influenza resistant and transgenic
quails have been efficiently generated by use of reporter genes, the expression of ≥4 shRNAs
from the same lentiviral vector has not been demonstrated. A proof of the concept of influenza
resistance in a chicken or bird model, such as quail, also remains to be demonstrated.
Second, to be commercially viable, influenza-resistant chickens and ducks have to be produced
in commercial pedigree lines. Introduction of transgenes into the pedigree lines would require
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the cooperation of commercial entities. Field testing of influenza resistance in transgenic
chickens and ducks will require regulatory approval and close monitoring. In addition, to
generate a large number (i.e., millions) of influenza-resistant chickens or ducks for commercial
distribution from the same founder will be likely to take years and to require extremely stable
transmission and expression of the transgene from generation to generation.
Third, transgenic poultry will be regarded as genetically modified organisms (GMOs). Since
transgenic siRNA sequences are from the influenza virus genome, they should not pose any
risk of influenza viruses acquiring novel or alien sequences. Resistance to GMO-based food
in industrialized countries may prevent their introduction into the poultry industry in the near
future. However, Asian countries, where frequent influenza outbreaks originate and where
variants of epidemic- and pandemic-causing influenza virus usually arise, are likely to be more
receptive to the introduction of influenza-resistant poultry. Influenza-resistant chickens and
ducks may prove particularly effective in hindering the development and spread of disease in
Asian countries where poultry farming is usually dispersed and is done in a family’s backyard.
In the long term, the introduction of influenza-resistant poultry, even in only some Asian
countries, might reduce the frequency of influenza epidemics and pandemics in poultry
populations, which in turn should reduce the frequency of global influenza epidemics and
pandemics in human populations, leading to significant economic, social, and health benefits.
The development and distribution of influenza-resistant poultry represents a proactive strategy
for controlling influenza epidemics and pandemics at their origin, in both poultry and human
populations, and complements current approaches for influenza control by means of vaccines
and antiviral drugs. However, the development and distribution of influenza-resistant poultry
will be likely to require years and maybe even decades of research and development, as well
as close collaboration among different entities. Nevertheless, the potential long-term economic
and health benefits should justify the initial investment in research and development.
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